Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

61 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The relationship of health-related quality of life to prevalent and incident vertebral fractures in postmenopausal women with osteoporosis: results from the Multiple Outcomes of Raloxifene Evaluation Study.
Silverman SL, Minshall ME, Shen W, Harper KD, Xie S; Health-Related Quality of Life Subgroup of the Multiple Outcomes of Raloxifene Evaluation Study. Silverman SL, et al. Among authors: harper kd. Arthritis Rheum. 2001 Nov;44(11):2611-9. doi: 10.1002/1529-0131(200111)44:11<2611::aid-art441>3.0.co;2-n. Arthritis Rheum. 2001. PMID: 11710717 Free article.
Post hoc analysis of data from the Multiple Outcomes of Raloxifene Evaluation (MORE) trial on the effects of three years of raloxifene treatment on glycemic control and cardiovascular disease risk factors in women with and without type 2 diabetes.
Barrett-Connor E, Ensrud KE, Harper K, Mason TM, Sashegyi A, Krueger KA, Anderson PW. Barrett-Connor E, et al. Clin Ther. 2003 Mar;25(3):919-30. doi: 10.1016/s0149-2918(03)80114-5. Clin Ther. 2003. PMID: 12852708 Clinical Trial.
Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial.
Delmas PD, Ensrud KE, Adachi JD, Harper KD, Sarkar S, Gennari C, Reginster JY, Pols HA, Recker RR, Harris ST, Wu W, Genant HK, Black DM, Eastell R; Mulitple Outcomes of Raloxifene Evaluation Investigators. Delmas PD, et al. Among authors: harper kd. J Clin Endocrinol Metab. 2002 Aug;87(8):3609-17. doi: 10.1210/jcem.87.8.8750. J Clin Endocrinol Metab. 2002. PMID: 12161484 Clinical Trial.
Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial.
Barrett-Connor E, Grady D, Sashegyi A, Anderson PW, Cox DA, Hoszowski K, Rautaharju P, Harper KD; MORE Investigators (Multiple Outcomes of Raloxifene Evaluation). Barrett-Connor E, et al. Among authors: harper kd. JAMA. 2002 Feb 20;287(7):847-57. doi: 10.1001/jama.287.7.847. JAMA. 2002. PMID: 11851576 Clinical Trial.
Effects of raloxifene hydrochloride on bone mineral density, bone metabolism and serum lipids in Chinese postmenopausal women with osteoporosis: a multi-center, randomized, placebo-controlled clinical trial.
Liu JL, Zhu HM, Huang QR, Zhang ZL, Li HL, Qin YJ, Zhang Y, Wei DL, Lu JH, Liu H, Chen XP, Liu YJ, Ekangaki A, Zheng YM, Diez-Perez A, Harper K. Liu JL, et al. Chin Med J (Engl). 2004 Jul;117(7):1029-35. Chin Med J (Engl). 2004. PMID: 15265377 Clinical Trial.
61 results